
|Articles|November 19, 2013
- Immunotherapy (Issue 1)
- Volume 1
- Issue 1
The Outlook for Immunotherapies
Author(s)Julie R. Brahmer, MD
Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.
Advertisement
Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.
Learn more aboutimmunotherapies in cancer
Articles in this issue
over 12 years ago
MPDL3280A Induces Durable Responses in NSCLC, Other Cancersover 12 years ago
Immunotherapy—An Increasingly Important Role in Oncologyover 12 years ago
Suzanne Topalian, MD, on PD-1 Targeted Therapyover 12 years ago
PD-1 and PD-L1 Antibodies in Lung Cancerover 12 years ago
Checkpoint Inhibitors in Cancer Careover 12 years ago
Search for Predictive Biomarkers of PD-1 Pathway Blockadeover 12 years ago
Nivolumab Plus Ipilimumab in Advanced MelanomaAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































